About
4SC AG is a biopharmaceutical company focused on discovering and developing small-molecule therapeutics primarily for oncology, with an emphasis on targeted kinase and epigenetic inhibitors. As of late 2025, the company has no ongoing clinical trials or active products under development.
Explore 4SC AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.